User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Inhibition of in-vitro simvastatin metabolism in rat liver microsomes by bergamottin, a component of grapefruit juice

Primary tabs

Le Goff-Klein, N Klein, L Herin, M. Koffel, JC Ubeaud, G

Grapefruit juice can modify the pharmacokinetic parameters of many drugs, in particular simvastatin, an orally active cholesterol-lowering agent. The exact components in grapefruit juice responsible for drug interactions are not perfectly known. However, it seems that bergamottin, a furocoumarin derivative, is one of the main active components within grapefruit juice. The objective of this paper was to quantify and to characterize in-vitro the inhibitory effect of bergamottin on simvastatin metabolism by using rat and human liver microsomes. In rat liver microsomes, the incubation conditions (+/-NADPH) of bergamottin were found to influence its inhibiting capacity. In co-incubation with simvastatin, the K-i value (the equilibrium dissociation constant for the enzyme-inhibitor complex) was higher (K-i = 174 +/- 36 muM) than in pre-incubation (K-i = 45 +/- 6 muM and 4 +/- 2 muM, without and with NADPH, respectively). It thus seems that the pre-incubation of bergamottin (in particular with NADPH) increases its inhibiting capacity on simvastatin metabolism. Bergamottin metabolism study in rat liver microsomes showed the formation of two metabolites that Were CYP-450 dependent. In contrast, in human liver microsomes, the incubation conditions of bergamottin did not influence its inhibiting capacity of simvastatin metabolism (K-i = 34 +/- 5 muM, K-i = 22 +/- 5 muM, K-i = 27 +/- 11 muM in co-incubation and pre-incubation without and with NADPH, respectively). In rat and man, bergamottin was found to be a mixed-type inhibitor of simvastatin hepatic metabolism. However, in rat, bergamottin was partially a mechanism-based inhibitor by involvement of either bergamottin alone or one of its metabolites. The results highlight the importance of validating in-vitro models to help verify the suitability of the in-vitro model for predicting the nature and degree of metabolic drug interactions.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2004
Language Anglais
Journal information "Journal of Pharmacy and Pharmacology : an international journal of pharmaceutical science" - Vol. 56, no. 8, p. 1007-1014 (2004)
Peer reviewed yes
Publisher Royal Pharmaceutical Soc Great Britain (London)
issn 0022-3573
Publication status Publié
Affiliation UCL
Links
  1. Alberts A. W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Schonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J., Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent., 10.1073/pnas.77.7.3957
  2. Bogman Katrijn, Peyer Anne-Kathrin, Török Michael, Küsters Ernst, Drewe Jürgen, HMG-CoA reductase inhibitors and P-glycoprotein modulation, 10.1038/sj.bjp.0703920
  3. Bourrie, J. Pharmacol. Exp. Ther., 277, 321 (1996)
  4. Bradford Marion M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, 10.1016/0003-2697(76)90527-3
  5. Carlucci G., Mazzeo P., Biordi L., Bologna M., Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection, 10.1016/0731-7085(92)80098-8
  6. Chang, J. Pharmacol. Exp. Ther., 299, 874 (2001)
  7. Condorcet, Transformation and estimating Michaelis-Menten parameters (1996)
  8. Di Marco Marika Pasternyk, Edwards David J, Wainer Irving W, Ducharme Murray P, The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: The role of gut CYP3A and P-glycoprotein, 10.1016/s0024-3205(02)01799-x
  9. EDWARDS D, FITZSIMMONS M, SCHUETZ E, YASUDA K, DUCHARME M, WARBASSE L, WOSTER P, SCHUETZ J, WATKINS P, 6 ́,7 ́-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein, 10.1016/s0009-9236(99)70102-5
  10. Guo, Drug Metab. Dispos., 28, 766 (2000)
  11. He Kan, Iyer Krishna R., Hayes Roger N., Sinz Michael W., Woolf Thomas F., Hollenberg Paul F., Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice, 10.1021/tx970192k
  12. Ho Ping C, Saville Dorothy J, Coville Peter F, Wanwimolruk Sompon, Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products, 10.1016/s0031-6865(99)00062-x
  13. Ho, J. Pharm. Pharm. Sci., 4, 217 (2001)
  14. Igel M., Sudhop T., von Bergmann K., Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins), 10.1007/s002280100329
  15. Kakkar, Drug Metab. Dispos., 27, 756 (1999)
  16. Koenigs Luke L., Trager William F., Mechanism-Based Inactivation of P450 2A6 by Furanocoumarins†, 10.1021/bi980003c
  17. Kupferschmidt Hugo H. T., Fattinger Karin E., Ha Huy Riem, Follath Ferenc, Krähenbühl Stephan, Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man : Grapefruit juice enhances bioavailability of saquinavir, 10.1046/j.1365-2125.1998.t01-1-00687.x
  18. Le Goff N., Koffel J. C., Vandenschrieck S., Jung L., Ubeaud G., Comparison of in vitro hepatic models for the prediction of metabolic interaction between simvastatin and naringenin, 10.1007/bf03192333
  19. Le Goff-Klein Nathalie, Koffel Jean-Claude, Jung Louis, Ubeaud Geneviève, In vitro inhibition of simvastatin metabolism, a HMG-CoA reductase inhibitor in human and rat liver by bergamottin, a component of grapefruit juice, 10.1016/s0928-0987(02)00222-1
  20. Lilja Jari J., Kivistö Kari T., Neuvonen Pertti J., Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors*, 10.1016/s0009-9236(98)90130-8
  21. Lilja J, Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin, 10.1067/mcp.2000.110216
  22. Mauro Vincent F., Clinical Pharmacokinetics and Practical Applications of Simvastatin : , 10.2165/00003088-199324030-00002
  23. Miniscalco, J. Pharmacol. Exp. Ther., 261, 1195 (1992)
  24. Ohta T, Dihydroxybergamottin Caproate as a Potent and Stable CYP3A4 Inhibitor, 10.1016/s0968-0896(01)00362-5
  25. Omura, Anal. Biochem., 239, 2379 (1964)
  26. Prueksaritanont, Drug Metab. Dispos., 25, 1191 (1997)
  27. Ross Samir A, Ziska David S, Zhao Ke, ElSohly Mahmoud A, Variance of common flavonoids by brand of grapefruit juice, 10.1016/s0367-326x(99)00131-8
  28. Ubeaud G., Hagenbach J., Vandenschrieck S., Jung L., Koffel J.C., In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin, 10.1016/s0024-3205(99)00380-x
  29. Voet, Biochemistry, 342 (1990)
Bibliographic reference Le Goff-Klein, N ; Klein, L ; Herin, M. ; Koffel, JC ; Ubeaud, G. Inhibition of in-vitro simvastatin metabolism in rat liver microsomes by bergamottin, a component of grapefruit juice. In: Journal of Pharmacy and Pharmacology : an international journal of pharmaceutical science, Vol. 56, no. 8, p. 1007-1014 (2004)
Permanent URL http://hdl.handle.net/2078.1/40009